TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · major macro event coming up
MRK

Merck & Company Inc

Healthcare · Drug Manufacturers - General

148.80$ +0.5% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios MRK
Line item 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Valuation
24.3 27.0 32.7 26.2 30.8 17.9 17.2 14.5 11.7 14.4 20.5 37.1 8.0 6.1 124.5 17.7 19.5 32.5 13.3 32.2 40.0 61.7 31.4 22.7 28.1 14.9 19.4 760.6 14.8 14.5
4.8 5.3 6.4 4.7 5.2 6.1 5.7 4.4 3.0 3.0 4.0 5.0 2.6 2.9 2.3 2.3 2.5 3.3 3.8 3.6 3.9 3.7 4.6 5.7 4.8 4.0 4.8 4.6 3.9 4.1
7.9 9.9 13.4 11.6 14.2 8.1 6.8 6.4 3.9 3.7 5.2 6.7 3.3 1.3 2.0 2.0 2.3 2.9 3.3 3.2 3.9 4.3 7.3 8.6 7.8 5.1 6.1 7.4 5.5 5.0
4.7 5.3 6.3 4.7 5.3 6.5 6.0 4.7 3.1 3.0 4.1 5.0 2.7 3.2 2.5 2.4 2.7 3.5 4.1 4.1 4.4 4.1 5.0 6.1 5.4 4.5 5.1 5.1 4.3 4.6
15.9 18.6 23.0 17.1 20.1 13.2 12.5 10.6 8.8 8.6 15.4 16.0 5.4 4.8 11.7 7.5 7.7 11.4 7.0 12.9 16.2 13.9 15.2 21.1 21.8 12.3 14.1 44.3 10.8 10.6
22.3 25.6 51.2 43.2 42.4 20.5 17.2 12.5 9.6 10.8 15.7 20.3 8.7 41.0 10.9 10.4 14.9 14.2 24.3 12.7 17.9 32.4 23.5 22.5 35.6 20.1 19.2 30.4 14.0 21.4
4.5% 3.9% 2.0% 2.3% 2.4% 4.9% 5.8% 8.0% 10.4% 9.3% 6.4% 4.9% 11.5% 2.4% 9.1% 9.6% 6.7% 7.1% 4.1% 7.9% 5.6% 3.1% 4.3% 4.5% 2.8% 5.0% 5.2% 3.3% 7.2% 4.7%
Margins
56.7% 53.7% 51.0% 49.9% 47.6% 82.9% 81.8% 80.3% 78.4% 76.6% 73.5% 74.6% 76.6% 67.1% 60.0% 64.9% 65.2% 61.5% 60.3% 62.2% 64.8% 67.8% 68.1% 69.3% 67.2% 72.0% 70.6% 73.2% 76.3% 72.0%
25.1% 24.8% 23.7% 23.2% 22.5% 43.8% 42.4% 38.1% 29.4% 26.6% 16.3% 23.2% 25.5% 14.7% 7.3% 18.7% 20.9% 17.4% 15.8% 19.1% 13.8% 16.9% 21.1% 20.3% 13.4% 27.1% 30.8% 4.9% 31.5% 36.2%
19.6% 19.5% 19.5% 18.0% 16.9% 34.3% 33.3% 30.4% 25.4% 21.0% 19.6% 13.5% 32.7% 47.0% 1.9% 13.1% 13.0% 10.0% 28.2% 11.2% 9.8% 6.0% 14.7% 25.2% 17.0% 26.8% 24.5% 0.6% 26.7% 28.1%
21.3% 20.6% 12.5% 10.9% 12.3% 30.0% 33.4% 35.3% 30.8% 28.2% 25.6% 24.7% 30.1% 7.0% 21.3% 22.2% 17.1% 23.0% 15.5% 28.5% 22.0% 11.4% 19.6% 25.5% 13.4% 19.8% 24.8% 15.2% 28.2% 19.0%
Returns
32.4% 36.6% 41.0% 44.5% 46.0% 45.4% 39.3% 43.9% 33.7% 25.8% 25.2% 18.0% 41.6% 21.8% 1.6% 11.5% 11.6% 8.8% 24.5% 9.9% 9.8% 7.0% 23.3% 38.0% 27.9% 34.2% 31.6% 1.0% 37.0% 34.7%
16.0% 17.9% 16.5% 16.5% 17.1% 16.5% 15.0% 16.8% 13.7% 10.3% 9.9% 6.8% 16.5% 11.5% 0.8% 6.0% 5.8% 4.2% 12.1% 4.4% 4.1% 2.7% 7.5% 11.7% 7.7% 12.3% 13.3% 0.3% 14.6% 13.3%
Balance Sheet & Debt
-746 -223 -1,982 837 4,383 6,721 6,306 5,595 3,994 -1,488 921 403 1,872 8,143 6,982 3,984 7,118 9,439 13,962 17,988 18,327 18,318 17,149 16,670 24,032 25,310 18,278 28,499 24,151 35,068
-0.1 0.0 -0.3 0.1 0.4 0.6 0.6 0.6 0.5 -0.2 0.2 0.1 0.2 0.4 0.7 0.3 0.4 0.7 0.6 1.4 1.7 1.5 1.2 1.5 2.4 1.4 0.9 4.1 0.9 1.2
49.3% 48.9% 40.2% 37.2% 37.2% 36.5% 38.3% 38.4% 40.6% 40.1% 39.4% 37.6% 39.7% 52.6% 51.4% 51.9% 50.0% 47.1% 49.6% 43.9% 42.0% 39.1% 32.3% 30.7% 27.6% 36.1% 42.1% 35.2% 39.5% 38.4%
0.1 0.1 0.0 0.2 0.5 0.6 0.5 0.4 0.4 0.5 0.4 0.3 0.3 0.3 0.3 0.3 0.4 0.5 0.4 0.6 0.6 0.7 0.9 1.0 1.3 0.9 0.7 0.9 0.8 0.9
Per Share
1.56 1.87 2.15 2.45 2.90 3.14 3.14 3.03 2.62 2.10 2.03 1.49 3.64 5.67 0.28 2.03 2.01 1.47 4.07 1.56 1.41 0.87 2.32 3.82 2.78 5.14 5.71 0.14 6.74 7.28
7.97 9.58 11.02 13.60 17.15 9.13 9.42 9.98 10.32 10.00 10.35 11.03 11.13 12.07 14.74 15.53 15.37 14.70 14.43 13.90 14.28 14.60 15.79 15.16 16.34 19.19 23.32 23.60 25.25 25.90
4.81 5.10 5.24 5.51 6.30 6.91 7.99 6.91 7.77 8.17 8.03 8.29 8.75 25.98 17.43 17.62 17.24 16.61 16.61 15.73 14.38 12.49 9.97 10.04 9.96 15.04 18.09 14.76 18.23 20.98
1.70 1.97 1.37 1.48 2.11 2.74 3.14 3.53 3.18 2.82 2.64 2.73 3.35 0.85 3.14 3.45 2.62 3.37 2.23 3.96 3.14 1.66 3.10 3.86 2.19 3.81 5.79 3.59 7.12 4.93

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?